STROMATIS PHARMA

Stromatis Pharma is developing a secreted frizzle-related protein 2 (sFRP2) antagonist for reverting stromal stellate cells. It focuses on developing antibodies to unique and unmet targets. It has a portfolio of five IP protected antibodies and a platform technology that effectively generates new proprietary antibodies The company’s leading drug candidate is CT109 MoAB that targets a key molecule (CD66c) associated with cancer dissemination and disease progression. Furthermore, CT109 targets ... a novel, patent-protected, epitope, ensuring sharp specificity On top of its antibodies portfolio, Stromatis licensed the rights to the DIAAD platform – a development platform enabling to produce high-affinity antibodies to endogenously expressed targets The lead product CT109 antibody and therapies with CT109 alone, in combination with other drugs or therapies and CT109-based Antibody Drug Conjugates (ADCs); The major indications planned now are on colorectal and pancreatic cancersMore